Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India

Completed

• Conditions: Dyslipidemia; Type 2 Diabetes Mellitus

• Registration Number: NCT01292018
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of study to assess the control of dyslipidemia in the Indian diabetic population treated with any hypolipidemic agent.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-01-31
• Study Start: 2011-02
• Study First Submitted QC: 2011-02-08
• Study First Posted: 2011-02-09
• Study Completion: 2012-02
• Status Verified: 2013-02
• Last Update Submitted: 2013-02-20
• Last Update Posted: 2013-02-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 5400

Inclusion Criteria

• Adult who is a known Type 2 diabetic as per the ADA 2010 criteria OR controlled diabetic (taking any antidiabetic medication)
• Patients in the study will have been on lipid lowering drugs at a stable dose for the last three months before the designated study visit.

Exclusion Criteria

• Type 1 diabetic patients
• Patients with a history of hepatic or renal diseases
• Hypertension due to organic diseases

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of type 2 diabetic dyslipidemia patients achieving the target LDL goal according to ADA 2010. These patients should be on stable dose of Lipid Lowering Drugs(LDL) for at least 3 months

Secondary Outcome Measures

Name	Time	Method
Proportion of dyslipidemia control rate according to american diabetes Association (ADA) 2010 criteria by age and gender
Control of dyslipidemia by Lipid Lowering Drugs (LLDs) drugs alone or combination
Control of dyslipidemia by all commercial available brands hypolipidemics drugs